Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial

被引：0
|
作者：
Dodick, D. [1 ]
Nahas, S. [2 ]
Pozo-Rosich, P. [3 ,4 ]
Bilchik, T. [5 ]
McAllister, P. [6 ]
Finnegan, M. [7 ]
Ma, J. [7 ]
Chalermpalanupap, T. [7 ]
Dabruzzo, B. [7 ]
Lipton, R. [8 ]
机构：
[1] Mayo Clin, Scottsdale, AZ USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Autonomous Univ Barcelona, Barcelona, Spain
[5] Yale Sch Med, New Haven, CT USA
[6] New England Inst Neurol & Headache, Stamford, CT USA
[7] AbbVie, Madison, NJ USA
[8] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2022年 / 23卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P110
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Subsequent response to atogepant in individuals with episodic migraine after an initial inadequate response: Post hoc analyses of a 12-week phase 3 trial
    Dodick, D. W.
    Nahas, S. J.
    Pozo-Rosich, P.
    Bilchik, T. R.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B. L.
    Lipton, R. B.
    HEADACHE, 2022, 62 : 164 - 165
  • [2] Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12-and 52-Week Phase 3 Trials
    Lipton, R.
    Nahas, S.
    Pozo-Rosich, P.
    Bilchik, T.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B.
    Dodick, D.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [3] Sustained response to atogepant in individuals with episodic migraine: Post hoc analyses of 12-and 52-week phase 3 trials
    Lipton, R. B.
    Nahas, S. J.
    Pozo-Rosich, P.
    Bilchik, T. R.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B. L.
    Dodick, D. W.
    HEADACHE, 2022, 62 : 165 - 166
  • [4] Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
    Lipton, Richard B.
    Nahas, Stephanie J.
    Pozo-Rosich, Patricia
    Bilchik, Tanya
    McAllister, Peter
    Finnegan, Michelle
    Liu, Yingyi
    Chalermpalanupap, Natty
    Dabruzzo, Brett
    Dodick, David W.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [5] Sustained and Subsequent Response to Atogepant Among Individuals With Episodic Migraine With Prior Treatment Failure: Post Hoc Analysis of the ELEVATE Trial
    Sacco, Simona
    Nagy, Krisztian
    Chalermpalanupap, Natty
    Vernieri, Fabrizio
    Smith, Jonathan H.
    Holle-Lee, Dagny
    Liu, Yingyi
    Carr, Karen
    Pozo-Rosich, Patricia
    Lipton, Richard B.
    CEPHALALGIA, 2023, 43 (1supp) : 265 - 266
  • [6] Sustained and Subsequent Response to Atogepant Among Individuals With Chronic Migraine: Post Hoc Analysis of the PROGRESS Trial
    Lipton, R.
    Chalermpalanupap, N.
    Nahas-Geiger, S.
    Pozo-Rosich, P.
    McAllister, P.
    Tatsuoka, Y.
    Liu, Y.
    Dabruzzo, B.
    Smith, J.
    Bilchik, T.
    HEADACHE, 2023, 63 : 168 - 169
  • [7] Sustained response to atogepant in individuals with episodic migraine and prior inadequate response to preventive treatment and in individuals with chronic migraine: post-hoc analyses from ELEVATE and PROGRESS
    Lipton, R. B.
    Chalermpalanupap, N.
    Tatsuoka, Y.
    Nagy, K.
    Liu, Y.
    Carr, K.
    McAllister, P.
    Nahas, S. J.
    Trugman, J. M.
    Sacco, S.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [8] Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 106 - 107
  • [9] Atogepant improved patient-reported migraine-specific quality of life in a 12-week phase 3 (ADVANCE) trial for preventive treatment of migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    HEADACHE, 2021, 61 : 43 - 44
  • [10] Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 158 - 159
12345